Related Experiment Video
Updated: Nov 29, 2025
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
11.1K
Alteration in cerebrospinal fluid (CSF) markers associated with α-synucleinopathies
Syed Ijlal Ahmed1, Farhan Khalid2, Syeda Beenish Bareeqa3
1Liaquat National Hospital and Medical College, Karachi, Pakistan.
European Archives of Psychiatry and Clinical Neuroscience
|November 22, 2020
Summary
Rapid eye movement sleep behavior disorder (RBD) is linked to Parkinson's disease and Lewy body dementia. Excluding RBD is crucial for accurate cerebrospinal fluid marker studies in these conditions.
Area of Science:
- Neuroscience
- Neurology
- Sleep Medicine
Background:
- Rapid eye movement sleep behavior disorder (RBD) is a prodromal marker for α-synucleinopathies.
- Parkinson's disease (PD) and Lewy body dementia (LBD) are α-synucleinopathies.
- RBD's association with PD and LBD necessitates its consideration in diagnostic research.
Discussion:
- The presence of RBD can confound the interpretation of cerebrospinal fluid (CSF) biomarkers in PD and LBD.
- Failure to account for RBD may lead to biased results and reduced specificity of diagnostic tests.
- Integrating RBD screening into research protocols can enhance the reliability of CSF marker studies.
Key Insights:
- RBD is a significant comorbidity that impacts biomarker studies in α-synucleinopathies.
- Exclusion or stratification of patients with RBD is vital for improving the diagnostic accuracy of CSF markers.
- Understanding the interplay between RBD and other neurodegenerative diseases is key for advancing research.
Outlook:
- Future research should incorporate systematic screening for RBD in PD and LBD cohorts.
- Developing refined diagnostic criteria that account for RBD will improve clinical utility of CSF markers.
- Further investigation into the shared pathophysiological mechanisms between RBD and α-synucleinopathies is warranted.
